Dear Doctor Letter (Rote-Hand-Brief) on Xofigo® (radium 223 dichloride): contraindicated in combination with abiraterone acetate and prednisolone/prednisone
2018.03.20
Active substance: radium 223 dichloride
The company Bayer AG issues information that an interim analysis of the randomised clinical trial in patients with castration-resistant metastatic prostate cancer has shown an increased risk of deaths and fractures in patients receiving radium 223 dichloride (Xofigo®) in combination with abiraterone acetate (Zytiga®) and prednisone/prednisolone.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN